富祥药业：他唑巴坦、舒巴坦是公司主要医药产品

Core Viewpoint - Fuxiang Pharmaceutical (300497) announced that its main pharmaceutical products, tazobactam and sulbactam, are expected to account for approximately 40% of the company's revenue in 2024 [1] Group 1 - The main raw material for tazobactam and sulbactam is 6-APA, which has seen a price decrease of 38% as of November 3, 2025, compared to the end of 2024 [1] - The decline in 6-APA prices is anticipated to effectively enhance the gross profit margin of the company's pharmaceutical manufacturing business [1]